- In April, 2020, the U.S. Food and Drug Administration (FDA) announced the approval of Biologics License Application for MenQuadfi Meningococcal (Groups A, C, Y, W) Conjugate Vaccine for the prevention of invasive meningococcal disease in persons 2 years of age and older. MenQuadfi was developed to elicit and demonstrate a strong immunological response in people of all ages, and it was well tolerated. MenQuadfi is designed to safeguard men of all ages
